Sanofi cuts 400 R&D jobs in PA

As part of Sanofi's push to consolidate R&D operations, the French drugmaker says it is closing its Great Valley, PA, R&D site by July 2011. That move will cost 400 workers their jobs. The roughly 45 clinical trial supply employees and support staff at the site won't be affected by the cuts.

Sanofi spokesperson Elizabeth Baxter tells The Mercury that the company is working to relocate as many employees as possible. "We anticipate that approximately 303 Great Valley-based employees will be offered relocation to another Sanofi Aventis U.S. site and approximately 105 Great Valley-based employees will be (terminated)." Oncology R&D workers will be moved to Cambridge, MA, while preclinical, clinical and regulatory jobs will head to Bridgewater, NJ, the paper reports. Thirty-five positions at the Bridgewater site are also being eliminated.

- read the article for more

Suggested Articles

Denali is partnering with Biogen on its Parkinson's disease program, netting a $560 million upfront fee and a $465 million investment.

In the first half of 2020, the regenerative medicine sector raised $10.7 billion, more than the total it raised in 2019.

The trial linked RG6346 to reductions in hepatitis B surface antigen that suggest the RNAi therapy can hold its own against drugs from J&J and Vir.